bn 80927 has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Prévost, G | 1 |
| Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O | 1 |
2 other study(ies) available for bn 80927 and Cancer of Prostate
| Article | Year |
|---|---|
BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2004 |
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |